Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa randomized double-blind placebo-controlled extension study of BAY 3401016 in adults with Alport syndrome
CTR20254337Phase 2Active
- Sponsor
- Bayer
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of BAY 3401016 in Alport syndrome, sponsored by Bayer. Started Feb 2026; status: active.
02
Drugs
BAY 3401016
03
Conditions
Alport syndrome
Beyond the preview
Go deeper on CTR20254337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254337.